AEON Biopharma (AEON) Announces CEO Change
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St set for lower open as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Anthropic's Claude AI identifies novel enzyme system in DNA search
AEON Biopharma Announces CEO Transition
March 27, 2025 4:05 PM EDTMarc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors
Jost Fischer, Chairman of AEON, will assume the role of interim CEO
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (AEON or the Company) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to... More
